Seattle, WA, United States of America

Patrick Secor

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Patrick Secor

Introduction

Patrick Secor is an accomplished inventor based in Seattle, WA. He has made significant contributions to the field of biotechnology, particularly in the development of methods to combat biofilm formation. With a total of 2 patents, Secor's work is at the forefront of medical innovation.

Latest Patents

Secor's latest patents include a monoclonal antibody and vaccine targeting filamentous bacteriophage. This invention describes a method for reducing or preventing biofilm formation in a human subject. The method involves administering a first composition that includes either an antigen-binding polypeptide that binds to Pf-family bacteriophage or a vaccine against Pf-family bacteriophage. Additionally, the patent outlines an antigen-binding polypeptide that specifically binds to a CoaB protein of Pf-family bacteriophage or a fragment thereof.

Career Highlights

Patrick Secor is currently associated with Inimmune Corporation, where he continues to push the boundaries of scientific research and innovation. His work is instrumental in developing solutions that address critical health challenges.

Collaborations

Secor has collaborated with notable professionals in his field, including Paul Laszlo Bollyky and William Parks. These partnerships enhance the impact of his research and contribute to the advancement of biotechnology.

Conclusion

Patrick Secor's innovative work in biotechnology, particularly in the development of monoclonal antibodies and vaccines, showcases his commitment to improving human health. His contributions are paving the way for future advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…